PE/Cyanine7 anti-human CD45 Antibody
- 产品名称：
- PE/Cyanine7 anti-human CD45 Antibody
- 产品类别：
- 抗体
- 产品编号：
- 368531
- 产品应用：
- 368531
[价格]
| 规格 |
价格 |
库存 |
| 25tests |
￥ 1656 |
1 |
- Verified Reactivity
- Human
- Antibody Type
- Monoclonal
- Host Species
- Mouse
- Immunogen
- Human PBMC
- Formulation
- Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
- Preparation
- The antibody was purified by affinity chromatography and conjugated with PE/Cyanine7 under optimal conditions.
- Concentration
- Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
- Application
-
FC - Quality tested
- Recommended Usage
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood.
- Excitation Laser
- Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
- Application Notes
It was found that the HI30 clone and the 2D1 clone can cross block each other's binding.
- Additional Product Notes
BioLegend is in the process of converting the name PE/Cy7 to PE/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our PE/Cyanine7 products. Please contact Technical Service if you have any questions.
- Application References
(PubMed link indicates BioLegend citation) -
- Bradstock KF, et al. 1980. J. Natl. Cancer Inst. 65:33.
- Csiba A, et al. 1984. Br. J. Cancer 50:699.
- Tchilian EZ, et al. 2001. J. Immunol. 166:1308.
- Lee MS, et al. 2004. Int. Immunol. 16:1109.
- Product Citations
-
- Ajith A, et al. 2021. Front Immunol. 12:687715. PubMed
- Carraro G, et al. 2021. Nat Med. 27:806. PubMed
- Zhang XN, et al. 2021. Cell Res. . PubMed
- Tu J, et al. 2022. Adv Sci (Weinh). 9:e2103631. PubMed
- Miao L, et al. 2021. Clin Transl Med. 11:e395. PubMed
- Mao FY, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:395. PubMed
- Jorapur A, et al. 2022. PLoS Pathog. 18:e1010200. PubMed
- Pedicona F, et al. 2022. Sci Signal. 15:eabl7989. PubMed
- Zeng Y et al. 2019. Immunity. 51(5):930-948 . PubMed
- Liu YG, et al. 2019. FASEB J. 33:5018. PubMed
- Lin G, et al. 2021. Mol Med Rep. 23:. PubMed
- Ajith A, et al. 2019. FASEB J. 33:5220. PubMed
- RRID
- AB_2715891 (BioLegend Cat. No. 368531) AB_2715892 (BioLegend Cat. No. 368532)
- Structure
- Type I transmembrane protein, 180 - 240 kD (multiple isoforms)
- Distribution
-
Hematopoietic cells, except circulating erythrocytes or platelets.
- Function
- Tyrosine phosphatases, signaling, co-stimulation (co-inhibition), TCR and BCR mediated activation.
- Ligand/Receptor
- Galectin-1, CD2, CD3, and CD4.
- Cell Type
- B cells, Dendritic cells, Neutrophils
- Biology Area
- Cell Biology, Immunology, Inhibitory Molecules, Neuroscience, Neuroscience Cell Markers
- Molecular Family
- CD Molecules, Protein Kinases/Phosphatase, TCRs
- Antigen References
-
1. Thomas M. 1989. Annu. Rev. Immunol. 7:339.
2. Trowbridge I, et al. 1994. Annu. Rev. Immunol. 12:85.
- Gene ID
- 5788 View all products for this Gene ID
- UniProt
- View information about CD45 on UniProt.org
